Literature DB >> 7052133

Characterization and partial purification of the plasminogen activator from human neuroblastoma cell line, SK-N-SH. A comparison with human urokinase.

L C Gilbert, J T Wachsman.   

Abstract

The plasminogen activator liberated by cells of human neuroblastoma strain SK-N-SH was purified up to 400-fold, with a 40% recovery of activity, by a relatively simple procedure. This involved (NH4)2SO4 precipitation, followed by chromatography on both Affi-Gel Blue and p-aminobenzaminidine-Sepharose. The SK-N-SH activator was shown to differ from human urokinase with respect to immunological specificity, the molecular weights and isoelectric points of their enzymatically active species, the ability to be activated by fibrin and their relative sensitivities to inactivation by diisopropyl fluorophosphate. The average molecular weights of the enzymatically active species derived from strain SK-N-SH were shown to be 66,500, 64,500, 60,500 and 37,500. In the presence of fibrin, the SK-N-SH plasminogen activator appeared to be stimulated approximately 16-fold, with no apparent stimulation of urokinase activity. Urokinase is inactivated by diisopropyl fluorophosphate at a rate 6.4-fold faster than that of the SK-N-SH activator.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7052133     DOI: 10.1016/0167-4838(82)90067-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  Effect of retinoic acid on human neuroblastoma: correlation between morphological differentiation and changes in plasminogen activator and inhibitor activity.

Authors:  L A Benjamin; R C McGarry; D A Hart
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Increased levels of plasminogen activator inhibitor-1 (PAI-1) in human brain tumors.

Authors:  J S Rao; A Rayford; R A Morantz; B W Festoff; R Sawaya
Journal:  J Neurooncol       Date:  1993-09       Impact factor: 4.130

3.  In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma.

Authors:  T Fisher; H Golan; G Schiby; S PriChen; R Smoum; I Moshe; N Peshes-Yaloz; A Castiel; D Waldman; R Gallily; R Mechoulam; A Toren
Journal:  Curr Oncol       Date:  2016-03-16       Impact factor: 3.677

4.  Pre-Clinical Evaluation of rHDL Encapsulated Retinoids for the Treatment of Neuroblastoma.

Authors:  Nirupama Sabnis; Suraj Pratap; Irina Akopova; Paul W Bowman; Andras G Lacko
Journal:  Front Pediatr       Date:  2013-03-21       Impact factor: 3.418

5.  RT-qPCR for PHOX2B mRNA is a highly specific and sensitive method to assess neuroblastoma minimal residual disease in testicular tissue.

Authors:  Victoria Grèze; Justyna Kanold; Fanny Chambon; Pascale Halle; Anne-Sophie Gremeau; Nathalie Rives; Nadège Rouel; Bruno Pereira; Andrei Tchirkov; Florence Brugnon
Journal:  Oncol Lett       Date:  2017-05-24       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.